Illustrative demonstration data. Not live, not verified, not medical or investment advice.
OncRef
Back to Falcon

CabozantinibCABOMETYX

Multi-targeted TKI (VEGFR, MET, AXL)

  • Renal cell carcinoma
    1L with nivolumab; 2L monotherapy · CheckMate 9ER, METEOR
    Approved
  • Hepatocellular carcinoma
    2L after sorafenib · CELESTIAL
    Approved
  • Differentiated thyroid cancer
    RAI-refractory, post-VEGFR · COSMIC-311
    Approved
  • Neuroendocrine tumors
    Previously treated pNET / epNET · CABINET
    Approved
  • Metastatic CRPC
    With atezolizumab · CONTACT-02
    Investigational

Zanzalintinib

Next-gen TKI (VEGFR, MET, TAM kinases)

  • Colorectal cancer
    Refractory mCRC with atezolizumab · STELLAR-303
    Investigational
  • Neuroendocrine tumors
    Advanced NET · STELLAR-311
    Investigational
  • Head & neck SCC
    1L with pembrolizumab · STELLAR-305
    Investigational
  • Renal cell carcinoma
    Non-clear cell, with nivolumab · STELLAR-304
    Investigational

Intelligence feed · 6 updates

What this means to you: Strengthens the differentiation story vs fruquintinib in the non-liver-met population — a likely focus for launch messaging.
Medical AffairsCommercialColorectal cancer
Traced to: Congress abstract (illustrative)

Competitive landscape

  • Lenvatinib + pembrolizumab
    Eisai / Merck · TKI + PD-1 · Renal cell carcinoma
    high
  • Axitinib + pembrolizumab
    Pfizer / Merck · TKI + PD-1 · Renal cell carcinoma
    high
  • Belzutifan
    Merck · HIF-2α inhibitor · Renal cell carcinoma
    medium
  • Atezolizumab + bevacizumab
    Roche · PD-L1 + VEGF · Hepatocellular carcinoma
    high
  • Durvalumab + tremelimumab
    AstraZeneca · PD-L1 + CTLA-4 · Hepatocellular carcinoma
    medium
  • Fruquintinib
    Takeda · VEGFR TKI · Colorectal cancer
    high
  • Trifluridine/tipiracil + bevacizumab
    Taiho · Chemo + VEGF · Colorectal cancer
    medium
  • Lutetium-177 dotatate
    Novartis · Radioligand · Neuroendocrine tumors
    high
  • Everolimus
    Novartis · mTOR inhibitor · Neuroendocrine tumors
    low
  • Lenvatinib
    Eisai · VEGFR TKI · Differentiated thyroid cancer
    medium

Key trials

  • STELLAR-303Phase 3
    Zanzalintinib + atezolizumab vs regorafenib
    Primary: Overall survival · Primary endpoint met
  • STELLAR-304Phase 3
    Zanzalintinib + nivolumab vs sunitinib (nccRCC)
    Primary: PFS, ORR · Enrolling
  • STELLAR-305Phase 2/3
    Zanzalintinib + pembrolizumab vs pembrolizumab
    Primary: PFS, OS · Enrolling
  • STELLAR-311Phase 3
    Zanzalintinib vs everolimus
    Primary: PFS · Enrolling
  • CABINETPhase 3
    Cabozantinib vs placebo
    Primary: PFS · Completed
  • CheckMate 9ERPhase 3
    Cabozantinib + nivolumab vs sunitinib
    Primary: PFS · Long-term follow-up